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Background. Cell mediated immunity, including efficient CTL response, is required to prevent HIV-1 from cell-to-cell
transmission. In previous investigations, we have shown that B1 peptide derived by Fourier transformation of HIV-1 primary
structures and sharing no sequence homology with the parent proteins was able to generate antiserum which recognizes
envelope and Tat proteins. Here we have investigated cellular immune response towards a novel non-homologous peptide,
referred to as cA1 peptide. Methodology/Principal Findings. The 20 amino acid sequence of cA1 peptide was predicted
using the notion of peptide hydropathic properties; the peptide is encoded by the complementary anti-sense DNA strand to
the sense strand of previously described non-homologous A1 peptide. In this report we demonstrate that the cA1 peptide can
be a target for major histocompatibility complex (MHC) class I-restricted cytotoxic T lymphocytes in HIV-1-infected or
envelope-immunized individuals. The cA1 peptide is recognized in association with different MHC class I allotypes and could
prime in vitro CTLs, derived from gp160-immunized individuals capable to recognize virus variants. Conclusions/
Significance. For the first time a theoretically designed immunogen involved in broad-based cell-immune memory activation
is described. Our findings may thus contribute to the advance in vaccine research by describing a novel strategy to develop
a synthetic AIDS vaccine.
Citation: Achour A, Biquard J-M, Krsmanovic V, M’Bika J-P, Ficheux D, et al (2007) Induction of Human Immunodeficiency Virus (HIV-1) Envelope
Specific Cell-Mediated Immunity by a Non-Homologous Synthetic Peptide. PLoS ONE 2(11): e1214. doi:10.1371/journal.pone.0001214
INTRODUCTION
A major objective of current HIV-1 vaccination strategies is the
induction of HIV-1-specific CD8+ MHC class I-restricted CTL
responses, suggested to play a pivotal role in viral clearance and
protection against HIV-1 disease progression [1]. In effect, the
studies from the simian-immunodeficiency virus (SIV) macaque
model show that CD8-specific monoclonal antibodies, which block
CTL activity, prevent an early viral load reduction [2–4]. Also, in
monkeys receiving experimental SIV vaccines and subsequently
infected with pathogenic SIV, the frequency of mutations within
CTL epitopes, presumably responsible for protection failure,
correlates with the level of viral replication [5]. More recently, it
was reported that a cellular-immunity based vaccine can affect the
progression of SIV in rhesus macaques [6]. As shown in earlier
experiments with influenza virus, the virus-induced CTLs
recognize short peptides derived by proteolytic degradation of
viral proteins and selected for presentation at the surface of
infected cells by association with MHC class I molecules [7].
However, despite the antigenic complexity of most viruses, the
CTL response to viral infection in many instances is dominated by
the reactivities directed against a limited number of immunodo-
minant peptidic epitopes. The identities of these epitopes are
controlled by the particular Major Histocompatibility Complex
(MHC) class I alleles of the host [7,8]. Furthermore, the marked
genetic diversity of HIV-1 and existence of distinct viral subtypes
or clades further hinders the development of a universally
efficacious HIV-1 vaccine. Thus, genetic variability of HIV-1,
especially of the envelope glycoprotein, remains the principal
obstacles for elaborating an efficient vaccine against AIDS [9].
Numerous methods, developed on the basis of characteristic
periodicities expressed by the discrete Fourier spectra, attempt to
introduce the relationship between function and structure of
proteins or protein-protein interactions [10–24]. They utilize
various physico-chemical indices of individual amino acids in
a protein sequence, especially those controlling their biological
activities, such as biorecognition. For example, a method referred
to as the Informational Spectrum Method (ISM, i.e. the EII/ISM
concept) [25,26], also named Resonant Recognition Model
(RRM) [27], is based on the estimated indices of electron ion-
interaction pseudo potential (EIIP) of delocalized electrons of the
amino acid residues [24]. In this method, the sequence of a given
protein is converted to a series of integer numbers allowing the
identification of spectral periodicities, i.e. characteristic frequencies
common for a family of proteins having a similar function [27–29].
Such characteristic spectral periodicities have been previously
identified for a number of protein families, including interacting
Academic Editor: Derya Unutmaz, New York University School of Medicine,
United States of America
Received September 22, 2007; Accepted October 19, 2007; Published November
28, 2007
Copyright:  2007 Achour et al. This is an open-access article distributed under
the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Funding: This research was supported by Centre National de la Recherche
Scientifique,(CNRS, France), National Research Council (NRC,Canada) and Associ-
ation pour le De ´veloppement des Biothe ´rapies expe ´rimentales ADBEA (Paris,
France).
Competing Interests: The authors have declared that no competing interests
exist.
* To whom correspondence should be addressed. E-mail: ammar.achour@univ-
paris5.fr
PLoS ONE | www.plosone.org 1 November 2007 | Issue 11 | e1214proteins such as certain growth factors and their receptor proteins
[30–33], although the phases corresponding to the common
characteristic frequencies of interacting proteins are found to be
opposite [27].
Based on the RRM protein-protein recognition concept, we
have previously developed the original approach of using non-
homologous peptides to induce antibodies against several proteins
of different HIV-1 strains, such as gp120 envelope [34] and TAT
proteins [35] that are important for HIV-1 replication and
modulation of cellular functions. In the previous work [34], we
have utilized a pair of synthetic non-homologous 20 amino acid
residue peptides, expressing two common characteristic frequen-
cies found by Fourier spectral analysis of CD4 binding fragments
of different HIV-1 envelope glycoprotein (gp120) isolates, referred
to as A1 peptide (KQQYYWYAWCQPPQDQLIMD) and B1
peptide (DDALYDDKNWDRAPQRCYYQ). We have shown
that the B1 peptide, which exhibits the same predicted
characteristic frequencies and phases as viral CD4 binding
fragments of HIV-1 isolates, is able to induce antibodies cross-
reacting with gp120 HIV-1 protein, while the antibodies induced
by the A1 peptide, which exhibits the opposite phases to both B1
peptide and gp120 protein at common characteristic frequencies,
did not cross-react with gp120 protein [34]. Thus, according to the
RRM concept, the pair of A1 and B1 peptides should be
considered as interacting peptides because they exhibit the
opposite phases at predicted common frequencies derived from
the viral CD4 binding fragments of HIV-1 isolates [34].
Following a parallel line of approach, several groups have
shown that the open reading frame of the antisense strand DNA
may encode ‘‘antisense’’ proteins and that the codons for
hydrophilic and hydrophobic amino acids on the sense DNA
strand correspond to the complementary codons specifying
hydrophobic and hydrophilic amino acids on the antisense strand
DNA [36–43]. Because of inverted hydropathy, the antisense
proteins can sometimes interact with the corresponding sense
proteins as demonstrated in the case of mRNA sequences for
epidermal growth factor (EGF), transferrin (TF) and interleukin-2
(IL-2), and mRNA sequences for their respective receptors, where
a complementarity was found in the region corresponding to the
ligand binding portion of the receptors [44–46].
In order to generate supplementary peptides as antigenic
analogs of both B1 peptide and gp120 envelope proteins of
HIV-1, we have combined the EIIP Fourier-based RRM
approach with peptide hydropathic properties specified by the
complementary DNA strand method. In this manuscript, we
describe the immunological properties of a new peptide whose
amino acid sequence was deduced from the complementary
(antisense) DNA strand to the sense DNA strand encoding the A1
peptide, which we called a complementary A1 peptide or cA1
peptide (VHNQLVLRRLAPSVPVVLLF). It should be noted that
according to the RRM concept the A1 and B1 peptides could be
considered as interacting pair of peptides because they exhibit the
opposite phases at predicted common frequencies established for
the viral CD4 binding fragments of the HIV-1 isolates [34]. Thus,
the ‘‘antisense’’ cA1 peptide was a candidate for an antigenic
homolog of both B1 peptide and gp120 envelop proteins of HIV-1.
This method was used to induce cellular immunity against HIV-1
and was validated in immunized rabbits as well as in T
lymphocytes originated from HIV-1 infected and envelope-
immunized individuals. Since rather poor information is available
regarding the cross-reactivity of envelope peptides in healthy
individuals immunized against the gp160 glycoprotein, we have
examined whether the artificially designed cA1 peptide could also
be recognized by CTLs derived either from individuals immunized
against divergent envelope proteins or from HIV-infected
individuals. In addition to the marked cytotoxic response to the
cA1 peptide, our results revealed the ability of this artificial peptide
to prime in vitro the CTLs from gp160 immunized individuals and
to generate T cell clones that recognized virus variants. Moreover,
the cA1 peptide was recognized by multiple HLA Class I
molecules. These findings are discussed with respect to the
potential value of the cA1 peptide in the design of an HIV vaccine.
MATERIALS AND METHODS
Generation and synthesis of the non-homologous
cA1 peptide
The nucleotide coding sequence of A1 peptide was deduced from
the A1 peptide amino acid sequence by selecting the correspond-
ing codons more frequently used in genes highly expressed in E.
coli [47]. The sequence designated ‘‘+’’ represents sense strand of
DNA (or messenger RNA when the base T is replaced by the base
U), while the chain designated ‘‘-’’ corresponds to complementary
antisense DNA strand, which was used as the coding sequence for
the cA1 peptide amino acid sequence, as shown in Table 1.
Peptide cA1 was synthesized on a Milligen 9050 apparatus with
Fmoc-Opfp/Hobt chemistry. The peptide was cleaved in
a conventional TFA (trifluoroacetic acid, CF3COOH) solution in
the presence of scavengers. The final precipitate was solubilized in
water and lyophilized. The crude peptide was dissolved in solution
A (0.1% TFA in water) and purified on a Vydac column (C18,
5 mm, 2561 cm) with a gradient over 90 min from 0 to 90% of
solution B (70% acetonitrile, 0.09% TFA solution in water) and
characterized on an electrospray mass spectrometer (SCIEX API
165) at 2269.4 amu as well as by HPLC (HP 1100) using analytical
Vydac column C18 in a gradient over 15 min from 30% to 70% of
solution B at a retention time of 14.1 min.
V3 loop Peptides synthesis and purification
Peptide 18IIIB was synthesized by the solid phase technique at
Peninsula Laboratories, Inc. (Belmont, CA) and purified by gel
filtration and ion exchange chromatography. The purified peptide
yielded a single peak on reverse phase HPLC on C.18 columns with
two different solvent systems, trifluoroacetic acid/water/acetonitrile,
and 0.05 M NaH2PO4/acetonitrile and exhibited the expected
amino-acid sequence. P18MN was synthesized under the same
conditions and was supplied for analytical studies by Dr. J. Berzofsky
(National Cancer Institute, Bethesda, MD, USA). P18SIMI peptide
was synthesized by Neosystems (Strasbourg, France).
Monoclonal antibodies
The monoclonal antibodies (mAbs), against human lymphocyte
surface markers: CD4 (OKT4), CD3 (OKT3) and CD8 (OKT8),
used for phenotypic analysis were purchased from ORTHO
Diagnostic Systems (New Jersey, USA).
HLA typing
HLA transplantation antigens were identified serologically in the
Tissue Typing Laboratory at Ho ˆpital Saint Louis (Paris) and
Centre National de Transfusion Sanguine (Paris) using a standard
complement-mediated cytotoxicity assay.
Isolation of lymphoid cells
Lymphocytes were isolated from peripheral blood by a Ficoll/
Hypaque density gradient method (Seromed, Berlin). All cells were
stored in liquid nitrogen after freezing in fetal calf serum
containing 10% DMSO.
Theoretically Designed Peptide
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Rabbits Rabbits were immunized with 300 mg of cA1 peptide
combined with complete or incomplete Freund’s adjuvant and
administered by intradermal injection. The injections (minimum
of 8 injections per animal) were administered every 10 days as
previously described [29].
Humans Recombinant vaccinia viruses (Lister strain)
expressing HIV-1 gp160 (LAV/IIIB, MN and RF strains) were
provided by Dr G. Beaud (Institut Jacques Monod, C.N.R.S.,
Paris, France) and prepared according to the procedure previously
described [48,49]. Soluble recombinant HIV-1 gpl60IIIB was
produced in mammalian cells by Drs F. Bex and A. Burny
(Universite ´ Libre de Bruxelles, Belgium). The recombinant
vaccinia virus carrying the env gene of one of SIMI’s viruses
(clone pULB5384) was used to prime a human volunteer, named
SH and to purify the envelope glycoprotein [50].
Immunized individuals
Donor BI was a healthy HIV-1-seronegative individual who gave
an informed consent to participate in this study [51]. Immuniza-
tions were performed in agreement with the requirements of the
French National Ethics Committee according to the following
protocol. He was immunized with recombinant vaccinia virus rV
(Lister strain) expressing HIV-1 gp160 (LAV/IIIB strain) given
intradermally. He was also boosted with 500 mg of gpl60IIIB as
a water-in-oil emulsion injected intramuscularly [51]. Donor SH
also gave an informed consent and was vaccinated by a standard
intradermal scarification with a stock of recombinant virus
expressing SIMI’s envelope glycoprotein [52]. Eleven weeks later,
donor SH was boosted with intramuscular injection of 150 mg
purified gp160SIMI adsorbed on alum as described [52]. The
study was approved by the local ethics committee as previously
published [51,52].
HIV-1-infected individuals
Frozen cells from 17 patients were collected for this study.
Informed consent was obtained from all subjects, as reported
previously [53]. For T-cell proliferation assays we have used cells
from 10 HIV-1-infected donors having CD4+ T cells ranging from
100 to 750/mm3 and plasma virus load varying from 300 to
50.000 HIV-1 RNA copies/ml. These donors were HLA
undetermined since they were consulted at Laennec Hospital in
Paris. Donors P3-P6 were HIV-1 positive individuals, sharing
MHC Class I A2 molecules and exhibiting a strong CTL response
against HIV-1 proteins. At the time of the study they began an
antiviral treatment and their CD4 number ranged from 350 to
900/mm3.
Polyclonal generation of CTLs
Human HIV-1-specific lymphocytes were generated in autologous
MLC (Mixed Lymphocyte Culture) with PBMC (Peripheral Blood
Mononuclear Cells) from donors by mixing 1610
6 cells with
2610
5 X-ray irradiated (100 Gy) HIV-1-infected autologous
phytohemagglutinin-stimulated blasts, where 15–30% of cells
expressed HIV-1 antigens [54].
Peptide induction of CTLs
In vitro stimulations of CTLs (46l0
6) were performed for 1 hour at
37uC in the presence of 10 mg/ml (1 mg in 100 ml) of cA1 peptide,
V3 loop P18IIIB peptide, or V3 loop P18SIMI peptide. After
being pulsed by these peptides, the cells were cultured and
resuspended at 10
6 cells/ml. Six days after the initiation, cultures
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6) were re-stimulated with
inactivated, but peptide-pulsed autologous PHA blasts cells (4610
6
cells, pulsed with 10 mg of peptide) in 2 ml of culture medium
supplemented with 20 U/ml recombinant IL-2 (Boehringer
Gmbh). Cultures were established in 24 well plates (Falcon,
USA) in RPMI1640 medium supplemented with 1 mM sodium
pyruvate, 2 mM L-glutamine, 100 u/ml penicillin, 100 mg/ml
streptomycin, 10% fetal calf serum (PAA, Austria) and 20 U/ml
recombinant IL-2 for 6 to 10 days. Subsequently, the established
CTL lines were maintained by weekly stimulation with IL-2-
supplemented culture medium [52].
Inhibition of specific cytotoxicity with monoclonal
antibodies
Prior to the initiation of the chromium release assay, effector cells
were incubated for 30 min with monoclonal antibodies against
CD3, CD4 and CD8 antigens (ORTHO Diagnostic Systems (New
Jersey, USA) to a concentration of 10 mg/ml.
Target cells
Lymphoblastoid cell lines (B-LCL) were generated from the PBMCs
of the donors by transformation with the supernatant from B95.8
strain of Epstein-Barr virus (EBV) cultures and were maintained in
RPMI1640 medium supplemented with 10% fetal bovine serum.
Recombinant viruses
Recombinant vaccinia viruses (Lister strain) expressing HIV-1
gp160 (LAV/IIIB, MN and RF strains) were prepared according
to the procedure previously described [52]. The recombinant
vaccinia virus was used to prime the individual SH and to purify
the envelope glycoprotein carried by the env gene of one of SIMI’s
viruses (clone pULB5384) [50].
T cell proliferation assay
In animal studies, blood samples were collected from rabbit ears
before and after immunization. Lymphocytes were separated on
a Ficoll buffy coat and washed twice. The cultures were carried out
Figure 1. The cA1 peptide-induced T cell proliferation. (A) Proliferation response in cA1 peptide-immunized rabbits. Lymphocytes collected before
and after immunization were stimulated with various concentrations of control B1 peptide, cA1 peptide or recombinant gp120 protein added to the
culture media. (B) Proliferation response of PBMCs from HIV-1-infected individuals. Cells were obtained from 10 HIV-1-infected individuals (1-10) and
their proliferation response was measured after stimulation with 1 mg/ml of control B1 peptide, cA1 peptide or after incubation without (-) peptide,
as indicated. The incorparation of [
3H]thymidine into DNA was measured 6 days after the stimulation. Tests were performed on triplicate samples.
doi:10.1371/journal.pone.0001214.g001
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supplemented with 1% antibiotics, glutamine, pyruvate and 10%
rabbit serum. The rabbit serum collected from the same animal
before immunization was heat inactivated for 30 min at 56uC.
Cells (2.5610
5 per well) were cultured with increasing amounts (1,
10 and 25 mg) of immunogens cA1 peptide, control peptide B1, or
HIV-1 gp120 recombinant baculovirus protein. From human
subjects, PBMCs were suspended in complete culture medium
containing 10% of heat inactivated normal human serum (AB
blood type). The cells (2.5610
5 per well) treated with medium
containing cA1 peptide or control B1 peptide and cultured in an
incubator at 37uC containing 5% of CO2. Five days after the
stimulation, [
3H] thymidine was added for 18 h, and its
incorporation into DNA was measured in a b counter.
Cytotoxicity assay
EBV transformed B cells (B-lymphoblastoid cell lines, referred to
as B-LCL) were infected with recombinant vaccinia virus (rV) or
wild-type vaccinia virus at 10 PFU/cell and incubated for
12 hours. These target-cells were then harvested, labelled with
100 mCi (1 Ci=37 GBq) of sodium [
5lCr]Chromate (Amersham)
for 60 min at 37uC, washed three times before being resuspended
to the appropriate concentration (5610
3 cells per well) for the use
as target cells [52]. For peptide testing, the cells were pulsed with
10 mg/ml of peptide [52] before labeling and lysis by the effector
cells was measured in a 4 hour chromium-release assay performed
in triplicate. The percentage of specific cytotoxicity was de-
termined using the formula: 1006[(release in assay-spontaneous
release)/(maximum release-spontaneous release)]. The maximum
release was determined by lysis of target-cells in 1 N HCl.
Spontaneous chromium release in medium alone ranged from 10
to 20%.
RESULTS
T-cell proliferation response
Immunized rabbits In cA1-immunized animals we have
observed a strong stimulation of lymphocytes sensitized by either
peptide cA1 or HIV1 gp120 recombinant protein, reaching
a highest proliferative activity at 1 mg/ml, as compared to cells
cultured with control B1 peptide (Fig 1A). The stimulation of
lymphocyte proliferative activity was higher in the presence of
gp120 protein when compared to the effect of cA1 peptide. By
Figure 2. CTL activities derived from cell cultures of 4 HIV-infected individuals (I, II, III and IV) directed against autologous target-cells
presenting cA1 peptide, control B1 peptide, or target-cells infected with either wild type vaccinia virus or recombinant vaccinia virus
expressing gp160MN. The CTL cultures were generated by polyclonal activation with the irradiated autologous cells. After a 10 day incubation the
effector cells were tested for CTL activity as described in materials and methods. The data are representative of 3 independent experiments
performed in triplicates. Standard errors of the mean (s.e.m) from triplicate wells were 5% of the mean.
doi:10.1371/journal.pone.0001214.g002
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before immunization. These results indicated that immunization
of rabbits with the artificial cA1 peptide could induce a cellular
response similar to HIV-1 gp120 protein. The possibility that the
cA1 peptide might be recognized by human immune cells in HIV-
1 infected individuals was further tested.
HIV-1-infected individuals We have then stimulated the
PBMCs, obtained from 10 randomly selected naturally infected
patients, with the cA1 peptide for 6 days and evaluated the ability of
T cells to proliferate using [
3H] thymidine incorporation into DNA.
As shown in Fig. 1B, the lymphocytes were able to proliferate in the
presence of cA1 peptide, while no significant specific proliferation
was observed when cells were incubated with the control B1 peptide.
It is noteworthy that T cells derived from healthy HIV-1-
seronegative individuals did not initiate proliferation in the
presence of cA1 peptide (data not shown), suggesting that the cA1
peptide recognition might have been processed after the viral
infection. No more cells were available to precise the nature of the
proliferating cell population. Although at the time of the study, no
HLA typing (Class I and II) was provided from the infected donors,
the lymphocyte proliferative activity of some cells in response to cA1
peptide may have had a CTL response.
Cytotoxic T-cell response in HIV-1-infected
individuals
Evaluation of cytotoxic T cells in HIV1-infected individuals is
generally achieved after a necessary step of in vitro stimulation. As
reported previously, HIV-specific CTLs were generated in mixed
leucocyte culture (MLC) with irradiated HIV-1-infected autolo-
gous stimulated blasts and used as effector cells in the assay [49].
Autologous lymphoblastoid cells were used as target-cells, which
were infected either with wild-type vaccinia virus or recombinant
gp160MN vaccinia virus, or pulsed with cA1 peptide or control B1
peptide. The results of each subject (1–4), identified by HLA Class
I status, are presented in Figure 2. No specfic lysis was obtained
when target-cells were infected with wild vaccinia virus or coated
with B1 peptide. By contrast, a cytotoxic response towards target-
cells expressing gp160MN protein (the latter being representative
of the most prevalent strains in Europe and North America) or
pulsed with the cA1 peptide, was observed. These results indicate
that the cA1 peptide could be recognized by HIV-1-specific CTLs
generated following standard activation.
Since the cA1 peptide was processed for recognition by HIV-1-
specific CTLs, we have evaluated the capacity of this peptide to
stimulate env-specific T cell memory from AIDS patients. Thus,
Figure 3. CTL activity of cA1-stimulated cell cultures of 4 HIV-infected individuals (I, II, III and IV) directed against autologous target-cells
presenting cA1 peptide, control B1 peptide, or target-cells infected with either wild type vaccinia virus or recombinant vaccinia virus
expressing gp160MN. The secondary cultures of the effector cells were obtained by incubating the PBMCs with the cA1 peptide and their CTL
activity was tested after 10 days of incubation. The data are representative of three independent experiments performed in triplicates. Standard
errors of the mean from triplicate wells were , 5% of the mean.
doi:10.1371/journal.pone.0001214.g003
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autologous stimulated blasts. The results, shown in Figure 3
illustrate that autologous target-cells expressing env antigen or
presenting cA1 peptide were killed very effectively by cA1-peptide
stimulated effector cells. This specific elimination of target-cells
appeared significantly higher when compared to the standard
activation assay (see Figure 2). By contrast, no specific killing was
observed by lymphocytes stimulated, under the same conditions,
by the control B1 peptide (data not shown).
It should be noted that all 4 individuals studied shared the HLA
Class I A*0201 molecule suggesting that the cA1 peptide might
share some common features with the MHC class I binding
peptides. To establish that we have explored the SYFPEITHI
database of T-cell epitopes and MHC ligands [55], typically used
to facilitate the search for binding peptides and the prediction of
T-cell epitopes [56]. As shown in Table 2, the cA1 peptide had
both preferred and auxiliary residues to be presented by the HLA-
A*0201 molecule, exhibiting a score at 29, compared to the well-
known epitope GILGFVFTL derived from the influenza protein,
which scores 30. By comparison, the control B1 peptide had only
auxiliary residues to be presented by the A*0201 molecule and
scores a maximum of 12. More interestingly the cA1 peptide
presents overlapping sequences (5–14; 9–18) to be presented to
HLA-A*0201 molecule as either nanomers or decamers.
Analysis of the CTL response in gp160 vaccinated
recipients
To evaluate the CTL response induced by the recombinant
vaccinia-env/gp160 regimen in human subjects, we performed in
vitro stimulation with V3 loop P18 peptide to activate and expand
the env-specific memory T cells in peripheral blood from the
vaccine recipients, as previously described [52]. Based on the
sequence analysis (Table 2), the cA1 peptide contained the anchor
residues for association with the HLA class I A*0201 molecule,
therefore, it could be recognized by the env-specific memory T
cells. Thus, cells were obtained from a healthy individual BI, who
was immunized with the recombinant vaccinia virus expressing the
HIV-1IIIB envelope gene and boosted with the purified
recombinant gp160IIIB protein (a strain, which did not cross-
react with divergent RF or America-Europe consensus MN strains)
as well as the cells from the donor SH, who was vaccinated with
recombinant vaccinia virus expressing SIMI envelope glycoprotein
cross-reacting with America-Europe consensus strain and was
boosted with SIMI gp160 protein. The cytolytic responses to the
HIV-1 envelope were tested 4 weeks after the last boost (51). The
immune cells from the donor BI were further stimulated in vitro
with P18IIIB in the presence of IL-2. These CTLs were able to kill
the autologous B-EBV LCL infected with recombinant vaccinia
virus expressing the whole gp160IIIB, but not the control target-
cells infected with wild-type vaccinia virus (Fig. 4, panel I). They
also killed the autologous B-EBV LCL pulsed with cA1 peptide,
while the cells pulsed with control peptide B1 survived (Fig. 4/I).
The CTLs derived from the donor SH and stimulated in vitro with
P18IIISIMI peptide were able to lyse the autologous B-EBV LCL
infected with recombinant vaccinia virus expressing the whole
gp160SIMI protein, but not the control target-cells infected with
wild-type vaccinia virus. Moreover, targets pulsed with the cA1
peptide were also killed (Fig. 4 panel, III).
Subsequently, we have evaluated the capacity of cA1 peptide to
stimulate envelope-specific CTLs in human subjects immunized
with recombinant vaccinia-env/gp160 proteins. The cA1 peptide
was used to activate and expand env-specific memory T cells in
lymphocytes from the vaccine recipients. Following 10 days of
stimulation in vitro, the responding T cells were assayed for specific
cytotoxicity. The CTLs from the donor BI, stimulated with cA1
peptide in the presence of IL-2, were able to kill the autologous B-
EBV LCL infected with recombinant vaccinia virus expressing the
Table 2. Sequence motifs important for peptide binding to the human MHC class I molecule HLA-A*0201and cA1 peptide structure
using SYFPEITHI database.
a
..................................................................................................................................................
VH N Q L V L R R L A P S
1 234567891 0 1 1 1 2 1 3
V PVVLLF
14 15 16 17 18 19 20
HLA-A*0201 nanomers HLA-A*0201 decamers
Position Sequence Score
b Position Sequence Score
b
9R L APSVPVV 29 9 R L APSVPVV L2 6
6V L RRLAPSV 25 10 L APSVPVV LL 2 2
11 A P SVPVVLL 19 5 L V LRLLAPS V2 1
10 L A PSVPVVL 18 8 R R LAPSVPV V1 7
8R R LAPSVPV 15 1 V H NQLVLRR L1 6
2H N QLVLRRL 14 4 Q L VLRRLAP S1 6
5L V LRRLAPS 14 7 L R RLAPSVP V1 4
4Q L VLRRLAP 12 6 V L RRLAPSV P1 1
1V H NQLVLRR 81 1 A P SVPVVLL F7
3N Q LVLRRLA 72 H N QLVLRRL A4
12 P S VPVVLLF 43 N Q LVLRRLA P2
7L R RLAPSVP 2
aHLA-A2-binding peptides are 8–10 amino acid (aa) residues long, with a Leu at position 2 (P2), and a Val or Leu at position 9. However, other peptide side chains (bold)
contribute to the stability of the interaction. In certain cases, the optimal length for peptide binding can be longer than 9 residues.
bThe allocation of values is based on the frequency of the respective amino acid in natural ligands, T-cell epitopes, or binding peptides.
doi:10.1371/journal.pone.0001214.t002
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PLoS ONE | www.plosone.org 7 November 2007 | Issue 11 | e1214whole gp160IIIB as well as the autologous B-EBV LCL pulsed
with cA1 peptide (Fig. 4 panel II). They did not kill, however, the
vaccinia virus infected target-cells expressing either gp160MN,
gp160SIMI, or cells infected with wild vaccinia virus (Fig. 4/II).
The CTLs from the donor SH, generated following activation
with the cA1 peptide, also developed the capability to kill target-
cells pulsed with the cA1 peptide (Fig. 4, Panel IV)). Most
interestingly, these effector cells were able to kill target-cells
infected with vaccinia virus expressing gp160 protein of the MN
strain, which may be regarded as representative of HIV-1 strains
prevalent in North America and Europe, as well as SIMI and the
highly divergent RF isolate strains. On the other hand, the target-
cells infected with recombinant vaccinia virus expressing IIIB/LAI
gp160 as well as target-cells infected with wild-type vaccinia virus
were insensitive to these CTLs from the donor SH (Fig. 4, panel IV).
Determination of the class I MHC restriction of the
cA1 peptide CTL determinant in gp160-immunized
individuals
The CTL cell lines were generated using a second stimulation with
irradiated, autologous PHA blasts pulsed with the reactive cA1
peptide. The effector cells from gp160IIIB immunized donor BI
(HLA-A*0201, -A*6801, -B*5101, -B*1301, -CW*0501) were
assayed for cytotoxicity on EBV-transformed cells. To determine
the MHC restriction, we have analyzed the cA1 peptide-specific
lysis towards target-cells, such as autologous B-LCLs, HLA class I
heterologous B-LCLs or B-LCLs, expressing the HLA-A*0201
molecule (Fig. 5/I). The data revealed that the recognition of cA1
peptide by effector cells specifically occurred in association with
the HLA-A*0201 molecule. Most interestingly, we have found that
the cA1 peptide was recognized by CTLs in association with HLA-
A*6801 and -B*5101 molecules, but not in association with HLA-
B*1301 and HLA-CW*0501.
Subsequently, we determined the class I MHC restriction of the
cA1 peptide CTL determinant in cells derived from SIMI gp160-
immunized individual SH (Fig. 5/II). Using a panel of B-EBV
transformed cells, we found that these specific CTLs recognized
the cA1 peptide by the A*0201 class I MHC molecule, the same
restriction element as the CTLs derived from gp160IIIB
immunized donor BI. Thus, these CTL lines specifically lysed
the autologous (HLA-A*0201, -A*2402, -B*4402, -B41,
-CW*0501, -DRB1*13, -DR-) lymphoblastoid cells pulsed with
cA1 peptide, while heterologous B-LCLs (HLA-A*01, A-,
-B*0801, -B*1401, -CW*0701, -C-, -DR-, -DRW-) cells, also
pulsed with cA1 peptide, were not lysed. The lysis was observed in
target-cells in which HLA-A*0201 and HLA-B*4402 were the
only shared restricting elements. Furthermore, the cA1 peptide
Figure 4. CTL activity of effector cells derived from the BI donor vaccinated with IIIB-env-recombinant protein and from the SH donor vaccinated
with SIMI-env-recombinant directed against autologous target-cells presenting cA1 peptide and HIV-1 env proteins. The secondary cultures of the
effectorcellsweregeneratedinvitroafterincubationwithV3loop P18 peptide( panelsI,III)andcA1 peptide(panelsII,IV).Thedataarerepresentativeof
four independent experiments performed in triplicates. Standard errors of the mean from triplicate cultures were all ,7% of the means.
doi:10.1371/journal.pone.0001214.g004
Theoretically Designed Peptide
PLoS ONE | www.plosone.org 8 November 2007 | Issue 11 | e1214was not recognized by the effector cells in association with HLA-
A*2402, HLA-B41, HLA-CW*0501 and HLA-DRB1*13. There-
fore, these results indicated that the class I HLA-A*0201 and -
B*4402 molecules were restrictive elements for the cA1 peptide in
immunized individual SH.
Determination of the phenotype of cA1-specific
effector cells
Since immunization might have primed CD4+ CTLs, we
determined the phenotype of the specific CTLs stimulated with
the cA1 peptide and derived from gp160IIIB (donor BI) and
gp160SIMI (donor SH) immunized individuals (Fig. 6). Accord-
ingly, we established that the cA1 peptide-specific CTLs were
conventional CD4- CD8+ CD3+ lymphocytes, because the
specific lysis was abrogated by the treatment with monoclonal
antibodies to CD8 and CD3 surface markers, but not with
antibody to CD4 molecule (Fig. 6).
DISCUSSION
T cells that mediate cellular immunity can detect the presence of
intracellular pathogens, because infected cells display on their
surface peptide fragments derived from the pathogen’s proteins, so
that T cells recognise the peptide–MHC molecule complex and
kill the infected cells. Thus, the MHC class I molecules deliver
peptides, originating in the cytosol, to the cell surface that are
recognised by CD8 T cells, while the MHC class II molecules
deliver peptides originating in the vesicular system to the cell
surface, where they are recognised by CD4 T cells. Previously, we
have reported that a non homologous synthetic peptide, selected
with techniques based on pattern property algorithm procedures,
can induce humoral response directed against the HIV-1 gp120 as
well as against the Tat proteins [34,35]. In the present study, we
have described a novel peptide, referred to as peptide cA1,
designed using the inverted hydropathy, i.e. complementary
[antisense] strand DNA method (as described in Introduction
and Material and Methods), which generated a cellular response
towards the recombinant gp120 protein in cA1 peptide-immu-
nized rabbit. Moreover, in vitro this peptide generated both the T
cell proliferation and CTL response in cells derived from either
naturally HIV-1 infected individuals or envelope-immunized
donors. Significantly, our data showed that the MHC-restricted,
peptide-specific CTLs were easily generated in vitro by the artificial
cA1 peptide alone, and that these CTLs were capable of lysing
target-cells expressing endogenous antigens in naturally infected
patients and in healthy gp160-immunized individuals. Therefore,
it is possible that the high frequency of env-specific CTL in
cultures not only reflects the high level of memory specific CTL
among PBMCs, but also a rapid expansion of these gp160-specific
killers in response to stimulation with cells presenting the cA1
peptide.
The cA1 peptide was also able to induce T helper cell response
in both cA1-immunized rabbits and HIV-infected individuals, as
demonstrated by cell proliferation assays. However, it remains
unclear whether this response reflected a threshold for intracellular
signalling or more complex events such as the action of co-
stimulatory molecules on the antigen presenting cells. The T
helper cells are also involved in the induction of CTLs by
responding to epitopes presented by the MHC class II molecules.
Although the T helper cells and CTLs generally respond to
different epitopes, the cA1 peptide could also induce T helper
cells. Therefore, it may be postulated that the dual recognition of
the cA1 peptide by both class I and II molecules contributed to its
efficient recognition. Despite the antigenic complexity of most
viruses, the CTL response to viral infection is, in many instances,
dominated by the reactivity directed against a limited number of
epitopes and their identity are rather controlled by the particular
MHC class I alleles of the host.
Although the HLA selectivity remains a problem for the
eventual vaccination with peptide sequences, we have found that
the cA1- peptide specific CTLs were restricted by more than one
class I molecule, including HLA-A*0201, -A*6801, -B*4402 and
HLA-B*5101 molecules. Our results are in accordance with the
SYFPEITHI database indicating effectively that cA1 peptide
shares anchor residues to be presented by HLA- A*0201, -A*6801,
-B*4402 and HLA-B*5101 molecules, the HLA-A*0201 family
Figure 5. The cA1 peptide-specific cytotoxicity of lymphocytes
originating from gp160IIIB-immunized individual BI (HLA-A*0201,
-A*6801, -B*5101, -B*1301, -CW*0501) (panel I) and from gp160SIMI-
immunized subject SH (HLA-A*0201, -A*2402, -B*4402, -B41,
-CW*0501, -DRB1*13, -DR-) (panel II ), both being HLA- A*0201 Class
I restricted. Autologous EBV-LCL (AUTO), heterologous (HETERO) or
cells sharing the HLA molecule with the donor were sensitized by cA1
peptide. Percentage of specific lysis was determined at the effector to
target (E/T) ratio of 10:1. The assays were performed in triplicate with
5000 target-cells/well.
doi:10.1371/journal.pone.0001214.g005
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locus. It is established that nine amino acids of the antigenic
peptide interact strongly with the MHC binding site, while two
A2-supermotifs are already defined in the literature [57]. As
indicated in the previous studies, most HLA-A*0201-binding
peptides are 9 amino acid residues long, with preferred aliphatic
residues at position 2 (P2) for Leu and for Val or Leu at position 9
(P9). Although not all nine amino acids interact strongly with the
MHC binding site, all of them contact and make significant
interactions with the MHC molecules [57]. Six of the peptide
amino acids fall into the pockets of the binding site; they are
defined as primary (positions 2 and 9) and secondary (positions 1,
3, 6 and 7) anchor positions. The remaining three amino acids are
accessible to solvent and can also interact with receptors on the T
cell, being able to affect MHC binding affinity in several ways -
through direct non-bonded interactions with the MHC, by causing
conformational changes in anchor residues and by altering the
dynamic properties of the whole peptide. However, further studies
are necessary to demonstrate whether or not the cA1 peptide can
be recognized in association with additional HLA class I and class
II allotypes.
Our study also points out a major problem in HIV-1 vaccine
development, which is antigenic sequence heterogeneity. The
ability of a vaccine to induce the cross-reactive CTLs, with a wide
Figure 6. Phenotype of cA1 peptide-specific CTLs derived from gp160IIIB-immunized individual BI (panel I) and from gp160SIMI-immunized
subject SH (panel II). Autologous B-LCLs, sensitized by cA1 peptide, were cultured with effector cells pre-treated with anti-CD8, anti-CD4 or anti-CD3
monoclonal antibodies. The control group was not treated with antibodies. Standard errors of the mean, from triplicate wells, were less than 5% of
the mean.
doi:10.1371/journal.pone.0001214.g006
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PLoS ONE | www.plosone.org 10 November 2007 | Issue 11 | e1214range of HIV-1 isolates, is of a great importance. Although the
hypervariability of the gp160 protein raises concern for the design
of a vaccine, it is encouraging that the cA1 peptide was able to
prime the CTLs against both RF and MN virus variants, the latter
being a representative of the most prevalent strains in Europe and
North America. Whatever is the mechanism involved, a broad-
based vaccination protocol producing group-specific CTLs is thus
a mandatory prerequisite for understanding a vaccination pro-
gram. Our observations suggest that the design of a vaccine should
take into account the selection of a broad array of epitopes from
different strains to confer a broad-based immunity (52).
Finally, this study further substantiates the concept that rational
design of various T-cell epitopes may lead to stronger peptide
immunogens. This strategy would allow the selection of beneficial
peptides recognizing a variety of viral proteins and/or strains in
association with multiple MHC class I alleles, excluding viral
epitopes responsible for the deleterious immune responses. The
findings reported here may be useful for developing an effective
vaccine designed to induce the cell-mediated immunity against
HIV-1.
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